Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Mastocytosis 4Recurrence 2Pruritus 2Piebaldism 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Mastocytosis, Systemic 2Gastrointestinal Stromal Tumors 2Blushing 2Ovarian Neoplasms 1Metastatic Castrate Resistant Prostate Cancer 1Melanoma 1Gastro-intestinal Stromal Tumours 1Gastro-Intestinal Stromal Tumour 1Gastro Intestinal Stromal Tumor 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Melanoma × masitinib × Clear all
NCT01280565 2020-11-05

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

AB Science

Phase 3 Terminated
134 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡